BOE Regenerative Medicine Technology Co., Ltd., Beijing 100015, China.
Children Heart Center, Fuwai Central China Cardiovascular Hospital, Zhengzhou 450018, China.
Cells. 2022 Sep 1;11(17):2732. doi: 10.3390/cells11172732.
Human umbilical cord-derived mesenchymal stem cell (UC-MSC) sheets have attracted much attention in cell therapy. However, the culture media and coating matrix used for the preparation of UC-MSC sheets have not been safe enough to comply with current clinical drug standards. Moreover, the UC-MSC sheet preservation systems developed before did not comply with Good Manufacturing Practice (GMP) regulations. In this study, the culture medium and coating matrix were developed for UC-MSC sheet production to comply with clinical drug standards. Additionally, the GMP-compliant preservation solution and method for the UC-MSC sheet were developed. Then, quality standards of the UC-MSC sheet were formulated according to national and international regulations for drugs. Finally, the production process of UC-MSC sheets on a large scale was standardized, and three batches of trial production were conducted and tested to meet the established quality standards. This research provides the possibility for clinical trials of UC-MSC sheet products in the development stage of new drugs and lays the foundation for industrial large-scale production after the new drug is launched.
人脐带间充质干细胞(UC-MSC)片在细胞治疗中受到广泛关注。然而,用于制备 UC-MSC 片的培养基和涂层基质还不够安全,无法符合当前的临床药物标准。此外,以前开发的 UC-MSC 片保存系统不符合良好生产规范(GMP)规定。在这项研究中,开发了符合临床药物标准的 UC-MSC 片生产用培养基和涂层基质。此外,还开发了符合 GMP 的 UC-MSC 片保存液和保存方法。然后,根据国家和国际药物法规制定了 UC-MSC 片的质量标准。最后,对 UC-MSC 片的大规模生产工艺进行了标准化,并进行了三批试生产,以满足既定的质量标准。这项研究为新药开发阶段的 UC-MSC 片产品临床试验提供了可能性,并为新药上市后的工业大规模生产奠定了基础。